Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation

Ivacaftor is gene-specific oral therapy for patients with cystic fibrosis who have a cystic fibrosis transmembrane conductance regulator mutation, G551D. To date, limited information is available about the benefit in patients with severe CF related lung disease, as such patients were excluded from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Michelle E, Smith, Daniel J, Reid, David W, Masel, Philip J, France, Megan W, Bell, Scott C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184528/
https://www.ncbi.nlm.nih.gov/pubmed/25473543
http://dx.doi.org/10.1002/rcr2.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184528/
https://www.ncbi.nlm.nih.gov/pubmed/25473543
http://dx.doi.org/10.1002/rcr2.27

Ejemplares similares